NasdaqGS:IMGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has ImmunoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.9%

IMGN

0.07%

US Biotechs

2.9%

US Market


1 Year Return

109.6%

IMGN

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: IMGN exceeded the US Biotechs industry which returned 24.7% over the past year.

Return vs Market: IMGN exceeded the US Market which returned 9.2% over the past year.


Shareholder returns

IMGNIndustryMarket
7 Day-1.9%0.07%2.9%
30 Day14.5%4.8%10.6%
90 Day9.5%10.5%5.1%
1 Year109.6%109.6%25.1%23.9%11.4%8.9%
3 Year4.6%4.6%32.9%28.5%34.3%25.4%
5 Year-67.7%-67.7%-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ImmunoGen undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: IMGN ($4.59) is trading above our estimate of fair value ($4.29)

Significantly Below Fair Value: IMGN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IMGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IMGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMGN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

25.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMGN's revenue (35.6% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: IMGN's revenue (35.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ImmunoGen performed over the past 5 years?

-8.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMGN is currently unprofitable.

Growing Profit Margin: IMGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMGN is unprofitable, and losses have increased over the past 5 years at a rate of -8.3% per year.

Accelerating Growth: Unable to compare IMGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: IMGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is ImmunoGen's financial position?


Financial Position Analysis

Short Term Liabilities: IMGN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IMGN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IMGN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: IMGN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMGN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 7.6% each year.


Next Steps

Dividend

What is ImmunoGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Mark Enyedy (55yo)

4.08yrs

Tenure

US$3,917,560

Compensation

Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and had been its Interim Principal Financial Officer since November 26, 2018. Mr. Enyedy is an In ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD3.92M) is about average for companies of similar size in the US market ($USD3.13M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Enyedy
President4.08yrsUS$3.92m0.25% $2.0m
Thomas Ryll
Senior Vice President of Technical Operationsno dataUS$1.57m0.043% $347.1k
Anna Berkenblit
Senior VP & Chief Medical Officer5.17yrsUS$1.81m0.056% $450.2k
David Foster
VP of Finance & Chief Accounting Officerno datano data0.012% $98.1k
Courtney O'Konek
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Audrey Bergan
VP & Chief Human Resources Officer1.92yrsno datano data
Theresa Wingrove
Senior Vice President of Regulatory Affairs & Qualityno datano data0.040% $323.6k
Stacy Coen
Senior VP & Chief Business Officerno datano datano data
Joseph Kenny
Secretaryno datano datano data

4.1yrs

Average Tenure

56.5yo

Average Age

Experienced Management: IMGN's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Enyedy
President4.08yrsUS$3.92m0.25% $2.0m
Stephen McCluski
Independent Chairman10.58yrsUS$124.77kno data
Dean Mitchell
Independent Director8.42yrsUS$88.77k0.0057% $45.9k
Kristine Peterson
Independent Director8.42yrsUS$98.77kno data
Richard Wallace
Independent Director12.58yrsUS$91.77kno data
Stuart Arbuckle
Independent Director2.42yrsUS$81.77kno data
Mark Goldberg
Independent Director8.58yrsUS$88.77k0.031% $247.0k

8.4yrs

Average Tenure

63yo

Average Age

Experienced Board: IMGN's board of directors are considered experienced (8.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.


Top Shareholders

Company Information

ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoGen, Inc.
  • Ticker: IMGN
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$800.523m
  • Shares outstanding: 174.41m
  • Website: https://www.immunogen.com

Number of Employees


Location

  • ImmunoGen, Inc.
  • 830 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1989
IMUDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1989
IMUXTRA (XETRA Trading Platform)YesCommon StockDEEURNov 1989
IMGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 1989

Biography

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 02:11
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.